| Alabama |
Home - Alabama Board Of Pharmacy |
Home | Alabama Board of Medical Examiners & Medical Licensure Commission |
Alabama Board of Nursing |
Alabama State Board of Medical Examiners Concerns with Semaglutide and
Other GLP-1 Receptor Agonists
July 18 2024 :The Alabama Board of Medical Examiners issued a Declaratory Ruling based on
the ALBOP request regarding the requirements for physician compounding of GLP-1 medications. The ALBME ruling states
that Alabama-licensed physicians “are required to comply with USP standards when compounding GLP-1 products.” Additionally,
the ruling states “physicians must purchase prescription products and ingredients only from an entity permitted by ALBOP.
https://www.albme.gov/press-release/fda-compounded-drug-products-containing-cagrilintide
|
| Alaska |
Board of Pharmacy, Professional Licensing, Division of Corporations, Business and Professional Licensing |
State Medical Board, Professional Licensing, Division of Corporations, Business and Professional Licensing |
Board of Nursing, Professional Licensing, Division of Corporations, Business and Professional Licensing |
|
| Arizona |
Home | State Board of Pharmacy |
AZ Medical Board |
Home | Board of Nursing |
FDA Letter regarding Retatrutide | Arizona Osteopathic Board
|
| Arkansas |
Arkansas State Board of Pharmacy - Arkansas Department of Health |
AR State Medical Board Home |
Arkansas State Board of Nursing - Arkansas Department of Health |
|
| California |
California State Board of Pharmacy |
Home | Medical Board of California |
California Board of Registered Nursing |
BOP Comments on GLP Sterility:
25_mar_bd_mat_general_comments.pdf
DECISION AFTER HEARING TO CONTEST CEASE AND DESIST ORDER:
cd_boothwyn.pdf
brd-AgendaItem3-20250515.pdf (SECURED)
|
| Colorado |
Pharmacy HOME | Divisions of Professions and Occupations |
Medical HOME | Divisions of Professions and Occupations |
Nursing HOME | Divisions of Professions and Occupations |
|
| Connecticut |
The Commission of Pharmacy |
Connecticut Medical Examining Board |
Registered Nurse Licensure |
Attorney General Tong Sues GLP-1 Weight Loss Drug Distributor Triggered Brand
|
| Delaware |
Board of Pharmacy - Division of Professional Regulation - State of Delaware |
Board of Medical Licensure and Discipline - Division of Professional Regulation - State of Delaware |
Board of Nursing - Division of Professional Regulation - State of Delaware |
|
| Florida |
Homepage - Florida Board of Pharmacy |
Homepage - Florida Board of Medicine |
Homepage - Florida Board of Nursing |
|
| Georgia |
Georgia Board of Pharmacy |
Georgia Composite Medical Board |
Georgia Board of Nursing | Georgia Secretary of State |
|
| Hawaii |
Professional & Vocational Licensing Division | Board Of Pharmacy |
Professional & Vocational Licensing Division | Hawaii Medical Board |
Professional & Vocational Licensing Division |
|
| Idaho |
Board of Pharmacy | Division of Occupational and Professional Licenses |
Board of Medicine | Division of Occupational and Professional Licenses |
Board of Nursing | Division of Occupational and Professional Licenses |
|
| Illinois |
IDFPR | State Board of Pharmacy |
IDFPR | State Medical Board |
IDFPR | Board of Nursing |
|
| Indiana |
PLA: Indiana Board of Pharmacy |
PLA: Medical Board |
PLA: Nursing Board |
|
| Iowa |
Board of Pharmacy | Department of Inspections, Appeals, & Licensing |
Board of Medicine | Department of Inspections, Appeals, & Licensing |
Nursing & Professional Midwifery | Department of Inspections, Appeals, & Licensing |
|
| Kansas |
Kansas Board of Pharmacy | Home |
Kansas Board of Pharmacy | Home |
Kansas Board of Pharmacy | Home |
Guidance on Compounding and Dispensing GLP1 and GIP.pdf |
| Kentucky |
Welcome - PHARMACY |
Welcome - Kentucky Board of Medical Licensure |
Welcome - KBN |
GLP-1 Compounding Guidance 2025.pdf
FDA Alert- GLP-1 Fraudulent Activity August 2025.pdf
Advanced Practice Registered Nurse FAQ - KBN
https://kbn.ky.gov/KBN%20Documents/aos16-meds-via-routes.pdf
|
| Louisiana |
LABP |
Home |
Home - Louisiana State Board of Nursing |
|
| Maine |
Board of Pharmacy | Office of Professional and Occupational Regulation |
Home | Maine Board of Licensure in Medicine |
Maine State Board of Nursing |
|
| Maryland |
Pages - MDH-BOP |
Maryland Board of Physicians |
Pages - Home |
BOP Minutes: Aug 20 - 2025 Public Agenda Minutes (1).pdf |
| Massachusetts |
Board of Registration in Pharmacy | Mass.gov |
Board of Registration in Medicine | Mass.gov |
Board of Registration in Nursing | Mass.gov |
|
| Michigan |
Pharmacy |
Medicine |
Nursing |
|
| Minnesota |
Minnesota Board of Pharmacy |
Minnesota Board of Medical Practice |
Minnesota Nursing Board |
July-2024-Minnesota-State-Newsletter_tcm21-632417.pdf |
| Mississippi |
Home | Mississippi Board of Pharmacy |
Home | Mississippi State Board of Medical Licensure |
Home | Mississippi Board of Nursing |
|
| Missouri |
Board of Pharmacy |
Physicians & Surgeons Home |
Board of Nursing |
|
| Montana |
Board of Pharmacy |
Board of Medical Examiners |
Board of Nursing |
|
| Nebraska |
Pharmacist |
Medicine and Surgery |
Nurse Licensing |
DUR May 13, 2025 Meeting Minutes.pdfc |
| Nevada |
Board of Pharmacy |
Medical Examiners Board |
Nevada State Board of Nursing – ….protecting the public’s health, safety and welfare through effective nursing regulation…. |
Notice to Compound Pharm re Tirzepatide semaglutide FINAL.pdf
Discussing a "statement of significant difference" for each prescription documenting a medical need specific to the patient for the compounded product." July 2025 Meeting Minutes FINAL - v6 - Board Approved.pdf |
| New Hampshire |
Board of Pharmacy | NH Office of Professional Licensure and Certification |
Board of Medicine | NH Office of Professional Licensure and Certification |
New Hampshire Board of Nursing | NH Office of Professional Licensure and Certification |
|
| New Jersey |
Pages - Board of Pharmacy |
NJ Division of Consumer Affairs - State Board of Medical Examiners |
NJDCAAPP |
GLP-1 Coalition Letter to New Jersey Board: Pharmacy-Minutes-08272025 (2).pdf
FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients: pharmacy-agenda-102225.pdf
|
| New Mexico |
Pharmacy Board | NM Licensing & Regulation Department |
State Medical Board of New Mexico - New Mexico Medical Board |
New Mexico Board of Nursing | Official Website |
|
| New York |
Pharmacy | Office of the Professions |
Medicine | Office of the Professions |
NYS Nursing: RN License Requirements |
|
| North Carolina |
Home |
North Carolina Medical Board |
Home | North Carolina Board of Nursing |
FDA ISSUES CLARIFYING STATEMENTS AND DEADLINES ON GLP-1 COMPOUNDING: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA
Lessons from NCMB’s Disciplinary Committee: Are you aiding the unlicensed practice of medicine? |
| North Dakota |
North Dakota Board of Pharmacy |
Home - ND Board of Medicine |
ND Board of Nursing |
|
| Ohio |
Ohio Board of Pharmacy |
State Medical Board | Ohio.gov |
Ohio Board of Nursing - Home | Ohio Board of Nursing |
Compounding of GLP-1 Drug Products in Ohio.pdf |
| Oklahoma |
Oklahoma State Board of Pharmacy |
Oklahoma Medical Board |
Oklahoma Board of Nursing (510) |
|
| Oregon |
Oregon Board of Pharmacy : Welcome Page : State of Oregon |
Oregon Medical Board : Oregon Medical Board : State of Oregon |
|
“If a pharmacy obtains semaglutide base for potential compounding use, the pharmacy must ensure that the API received is a pharmaceutical-grade product,
accompanied by a valid certificate of analysis, and is sourced from an establishment registered with the FDA under section 510 of the FD&C Act.
Therefore, “research use only” products, or products produced by establishments which are
not registered with the FDA, may not be used for compounding in any circumstance.” Oregon Board of Pharmacy : Position Statements : State of Oregon
“Oregon Medical Board physicians (MDs and DOs) and physician associates (PAs) are authorized to prescribe medications consistent with the
established standards of care, regardless of approval by the Food and Drug Administration (FDA).” Oregon Medical Board : Prescribing : Topics of Interest : State of Oregon
|
| Pennsylvania |
Pharmacy | Department of State | Commonwealth of Pennsylvania |
Medicine | Department of State | Commonwealth of Pennsylvania |
Nursing | Department of State | Commonwealth of Pennsylvania |
Ҥ 27.602. Compounding prohibited. Pharmacists may not compound any of the following:
(1) Drugs that have been identified by the FDA as withdrawn or removed from the market because the drugs were found to be
unsafe or ineffective as set forth in 21 CFR 216.24 (relating to drug products withdrawn or removed from the market for reasons of
safety or effectiveness) unless the drug is being used as part of a clinical trial and is approved by an institution's institutional review board. (2) Drugs
that are essentially copies of a commercially available drug product, except as provided in section 503a(b)(1)(D) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C.A. § 353a(b)(1)(D)). (3) Drugs that have been identified by the FDA in the Federal Food, Drug, and
Cosmetic Act (21 U.S.C.A. §§ 301—399h) or the Code of Federal Regulations as products which may not be compounded.” PharmM - Compounding
Regulations Finalized.pdf
Administration-of-Subcutaneous-GLP-1-Agonist-Medications-by-Unlicensed-Staff.pdf |
| Rhode Island |
Pharmacy | Department of Health |
Physicians | Department of Health |
Nurses | Department of Health |
|
| South Carolina |
SCLLR |
SCLLR |
SCLLR |
|
| South Dakota |
South Dakota Board of Pharmacy | South Dakota Department of Health |
South Dakota Board of Medical and Osteopathic Examiners |
Home - SD Board of Nursing |
|
| Tennessee |
Pharmacy |
Medical Examiners |
Nursing |
|
| Texas |
TSBP Website - Texas State Board of Pharmacy |
Texas.gov Original Licenses Application |
Welcome to the Texas Board of Nursing Website |
|
| Utah |
Pharmacy - dopl.utah.gov |
Physician and Surgeon - dopl.utah.gov |
Nursing - dopl.utah.gov |
|
| Vermont |
Pharmacy - Office of Professional Regulation, Vermont Secretary of State |
Board of Medical Practice | Vermont Department of Health |
Nursing - Office of Professional Regulation, Vermont Secretary of State |
|
| Virginia |
Virginia Board of Pharmacy |
Virginia Board of Medicine |
Virginia Board of Nursing |
|
| Washington |
Pharmacy Commission Information | |
Licensing | Washington |
Washington State Nurse Licensing | |
Reminder: Commission’s Statement on Compounding Semaglutide and GLP-1s | Washington State Board of Nursing |
| West Virginia |
Home - WV Board of Pharmacy |
Home - WV Board of Medicine |
WV RN Board |
|
| Wisconsin |
DSPS Pharmacy Examining Board |
DSPS Physician |
DSPS Nursing, Board of |
|
| Wyoming |
Pharmacy |
Board of Medicine |
WSBN |
|
